Does insurance cover GLP-1s for weight loss?
Usually only if your plan chose to include weight-loss drugs. Here is what the federal rules say, and what 20 insurers say on their own pages.
Read Sep 28, 2026. What your plan covers is in your own plan documents; these pages describe insurers in general.
Insurer by insurer
- Aetna
Aetna’s medical Clinical Policy Bulletin 0039 (Weight Reduction Programs and Devices; last review 03/10/2026) says many Aetna benefit plans exclude weight-reduction medications under the pharmacy and/or health benefit. aetna.com
- Anthem Blue Cross and Blue Shield
Anthem’s member pharmacy page says a drug on its drug list may still not be covered, depending on the member’s plan design. anthem.com
- Blue Cross and Blue Shield of Illinois
A May 20, 2025 BCBSIL provider notice says coverage for GLP-1 weight management drugs such as Saxenda, Wegovy and Zepbound is not a standard benefit for members. bcbsil.com
- Blue Shield of California
Blue Shield’s Nov. 1, 2024 provider announcement says that from Jan. 1, 2025 (or plan renewal after that), certain weight loss medications are no longer covered for some commercial PPO and HMO members unless Blue Shield authorizes them as medically necessary. blueshieldca.com
- Cigna
Cigna Healthcare’s newsroom (July 17, 2025) says Cigna Pharmacy has seen weight-management GLP-1 claims rise as more employers, about 20% as of the start of 2025, add this coverage. newsroom.cigna.com
- Florida Blue
Florida Blue’s Medicare Part D education page says that, due to federal regulation, Medicare does not cover drugs used for weight loss. floridablue.com
- Highmark
In an August 30, 2024 bulletin, Highmark said it was revising its prior authorization policy for certain weight-loss drugs for fully insured commercial and ACA members. providers.highmark.com
- Humana
Humana’s Medicare article (published 05/15/2026, updated 06/08/2026) says Medicare Part D doesn’t cover weight-loss medications used only for weight loss. humana.com
- Independence Blue Cross
IBX says that effective Jan. 1, 2025 it no longer covers GLP-1 or non-GLP-1 drugs indicated for and prescribed solely for weight loss when there is no other FDA-approved clinical indication. provcomm.ibx.com
- Kaiser Permanente
Kaiser Permanente’s general (not region-specific) “How our formulary works” page introduces a list of drug types that are not usually covered by the KP prescription drug benefit. healthy.kaiserpermanente.org
- Molina Healthcare
Molina Healthcare of Illinois (Medicaid) provider formulary page says some drugs are never covered, such as drugs for weight loss. molinahealthcare.com
- Oscar Health
Oscar states coverage is subject to the member’s policy terms and applicable state and federal law. hioscar.com
- Premera Blue Cross
Premera’s Feb. 12, 2026 formulary newsletter says weight-management GLP-1s are only covered when the employer group has elected the weight-loss drug benefit. producernews.premera.com
- UnitedHealthcare
UHC’s commercial clinical-pharmacy PA list has a program titled “Plans with Weight Loss/Appetite Suppression Medication Coverage” (i.e. for plans that include weight-loss drug coverage); its drug list includes Foundayo. uhcprovider.com
- Ambetter
Ambetter from Arkansas Health & Wellness member news dated 11/21/25 says Ambetter does not currently cover GLP-1s prescribed solely for weight management. ambetterhealth.com
- Wellcare
Wellcare says Medicare Part D plans do not cover GLP-1 drugs used only for weight loss. wellcare.com
- TRICARE
Express Scripts (the TRICARE pharmacy contractor) says weight loss medications such as Wegovy and Zepbound are covered for TRICARE Prime and TRICARE Select beneficiaries with an approved prior authorization. militaryrx.express-scripts.com
- FEP Blue (federal employees)
FEP Blue covers weight-loss drug prescriptions to treat obesity for members who meet eligibility criteria and get prior approval; covered drugs are listed in its formularies. fepblue.org
- BlueCross BlueShield of South Carolina
BCBS SC’s group-plan pharmacy page says some plans may exclude coverage of drug categories such as weight-loss drugs. southcarolinablues.com
- CareFirst BlueCross BlueShield
CareFirst provider news (posted June 3, 2025) says that from July 1, 2025 Zepbound is no longer covered on the F2, F3, F3 Choice, F2 CHART and F4 CHART formularies, with Wegovy and Saxenda remaining as alternatives. provider.carefirst.com
Employer and individual (ACA) plans: the federal rules
- Federal EHB drug rule for ACA plans (45 CFR 156.122(a)(1)) requires covering at least the greater of one drug in every USP category and class or the same number as the state’s EHB-benchmark plan; the CMS page does not name weight-loss drugs.Individual (ACA) plans:
Plans subject to EHB requirements must comply with 45 CFR 156.122(a)(1) to cover at least the same number of prescription drugs in every category and class in the United States Pharmacopeia (USP) Medicare Model Guidelines (MMG) as covered by the State's EHB-benchmark plan, or one drug in every category and class, whichever is greater.
cms.gov, Sep 29, 2026 - HealthCare.gov: EHB are minimum requirements for all Marketplace plans and the specific services in each category can vary by state.Individual (ACA) plans:
Essential health benefits are minimum requirements for all Marketplace plans. Specific services covered in each broad benefit category can vary based on your state’s requirements.
healthcare.gov, Sep 29, 2026 - CMS: HHS rules define EHB through state-specific EHB-benchmark plans, so the covered benefit set is set state by state.Individual (ACA) plans:
HHS regulations (45 CFR 156.100, et seq.) define EHB based on State-specific EHB-benchmark plans.
cms.gov, Sep 29, 2026 - HealthCare.gov: benefits are generally the same across states, but some states require extra services and plans in the same state can differ slightly.Individual (ACA) plans:
Generally, yes. But some states require insurers to cover additional services and procedures. Even within the same state, there can be small differences.
healthcare.gov, Sep 29, 2026 - HealthCare.gov: self-insured large employers do not have to provide essential health benefits.Employer and commercial plans:
It depends. Large employers who "self-insure” — meaning they pay employees' health care costs directly — don't have to provide essential health benefits. But many do.
healthcare.gov, Sep 29, 2026 - HealthCare.gov: Marketplace enrollees can use the insurer’s drug exceptions process to request a prescribed drug the plan does not normally cover; details differ by plan.Individual (ACA) plans:
If you can’t get a one-time refill, you have the right to follow your insurance company’s drug exceptions process, which allows you to get a prescribed drug that’s not normally covered by your health plan. Because the details of every plan’s exceptions process are different, you should contact your insurance company for more information.
healthcare.gov, Sep 29, 2026 - HealthCare.gov: each plan has a list of covered drugs linked when comparing plans or previewing plans before login.Individual (ACA) plans:
You can view a summary of benefits, a plan brochure, a provider directory, and a list of covered drugs for each plan. You’ll find links to all of these when you’re comparing Marketplace plans or previewing plans and prices before you log in.
healthcare.gov, Sep 29, 2026 - HealthCare.gov: shoppers can enter their prescription drugs when comparing plans and the site shows whether each plan covers them.Individual (ACA) plans:
You can also search for your doctors, medical facilities, and prescription drugs when you compare plans. Select your doctors, hospitals and other medical facilities, and prescription drugs. When you view plans, we’ll tell you if each one covers them in network.
healthcare.gov, Sep 29, 2026 - HealthCare.gov: enrolled members can check their plan’s covered-drug list on the insurer’s website.Individual (ACA) plans:
Visit your insurer’s website to review a list of prescriptions your plan covers
healthcare.gov, Sep 29, 2026
Medicare: the federal rules
- CMS fact sheet (Nov 26, 2024, CY2026 proposed rule): under current policy, anti-obesity medications are coverable in Part D only when used for another medically accepted indication, such as type 2 diabetes or MACE risk reduction in adults with established CVD and obesity or overweight.Medicare:
Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).
cms.gov, Sep 29, 2026 - CMS proposed rule in the Federal Register (Dec 10, 2024): drugs used for weight loss or chronic weight management can be covered by Part D plans only as a supplemental benefit.Medicare:
Drugs used for weight loss or chronic weight management can be covered by Part D plans only as a supplemental benefit.
federalregister.gov, Sep 29, 2026 - CMS final rule fact sheet (April 4, 2025): CMS did not finalize the proposed Part D coverage of anti-obesity medications or its application to Medicaid.Medicare:
CMS is also announcing that it is not finalizing three provisions from the proposed rule (Enhancing Health Equity Analyses: Annual Health Equity Analysis of Utilization Management Policies, Procedures and Ensuring Equitable Access to Medicare Advantage Services—Guardrails for Artificial Intelligence, and Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program).
cms.gov, Sep 29, 2026 - CMS: the Medicare GLP-1 Bridge is a short-term CMS demonstration giving eligible Part D enrollees access to certain GLP-1s from July 1, 2026 to Dec 31, 2027.Medicare:
The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.
cms.gov, Sep 29, 2026 - CMS: Bridge enrollees pay a $50 copay, and Bridge drugs are provided outside the Part D benefit payment flow and coverage.Medicare:
Eligible beneficiaries will have a $50 copay. Eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge are provided outside of the Part D benefit payment flow and coverage.
cms.gov, Sep 29, 2026 - CMS: drugs eligible under the Bridge are Foundayo, Wegovy (injection and tablets) and Zepbound KwikPen, when used to reduce and maintain excess body weight.Medicare:
At this time, for the purposes of the Medicare GLP-1 Bridge, an eligible GLP-1 drug is any of the following products when used to reduce excess body weight and maintain weight reduction: Foundayo®, Wegovy® (injection and tablets), and Zepbound® (KwikPen®).
cms.gov, Sep 29, 2026 - Medicare.gov: Bridge eligibility requires age 18+ and one of the listed BMI/condition requirements at the start of GLP-1 therapy.Medicare:
You must be 18 or older and meet one of these requirements when you start GLP-1 therapy:
medicare.gov, Sep 29, 2026 - Medicare.gov: one listed Bridge eligibility option is a BMI of 35 or higher (the page also lists BMI 30+ and BMI 27+ options that require specific conditions).Medicare:
You have a body mass index (BMI) of 35 or higher.
medicare.gov, Sep 29, 2026 - CMS: type 2 diabetes, moderate-to-severe obstructive sleep apnea and noncirrhotic MASH are indications eligible for regular Part D coverage.Medicare:
Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) indications are eligible for Part D coverage.
cms.gov, Sep 29, 2026 - Medicare.gov: a Bridge prior authorization stays valid, including refills and dose changes, through Dec 31, 2027 unless the person switches GLP-1s.Medicare:
Your prior authorization is valid (including for refills and dose changes) through December 31, 2027, unless you change GLP-1s.
medicare.gov, Sep 29, 2026 - CMS BALANCE Model page refers to the BALANCE Model not launching in Medicare in 2027.Medicare:
What is the impact of the BALANCE Model not launching in Medicare in 2027 on the Medicare GLP-1 Bridge?
cms.gov, Sep 29, 2026
The Medicare GLP-1 Bridge, in full and the eligibility check
Medicaid: the federal rules
- CMS proposed rule in the Federal Register (Dec 10, 2024): weight-loss drugs have historically been an optional Medicaid benefit, at each state Medicaid program’s discretion.Medicaid:
All drugs used for weight loss have been excluded historically from the definition of covered Part D drug and considered to be an optional benefit under the Medicaid program, at the discretion of the state Medicaid program, regardless of their use to treat the disease of obesity.
federalregister.gov, Sep 29, 2026 - CMS final rule fact sheet (April 4, 2025): the proposal to require Medicaid coverage of anti-obesity medications (together with Part D) was not finalized.Medicaid:
CMS is also announcing that it is not finalizing three provisions from the proposed rule (Enhancing Health Equity Analyses: Annual Health Equity Analysis of Utilization Management Policies, Procedures and Ensuring Equitable Access to Medicare Advantage Services—Guardrails for Artificial Intelligence, and Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program).
cms.gov, Sep 29, 2026 - CMS BALANCE Model page: Medicare and Medicaid currently generally do not cover GLP-1s for the weight loss indication.Medicaid:
Problem: GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.
cms.gov, Sep 29, 2026 - CMS: weight-loss coverage under the voluntary BALANCE Model launches in Medicaid as early as May 2026.Medicaid:
The coverage for weight loss under the BALANCE Model will launch in Medicaid as early as May 2026.
cms.gov, Sep 29, 2026 - CMS: BALANCE Medicaid coverage depends on manufacturer and state participation, and patients face negotiated qualifications including prior authorization.Medicaid:
Coverage in the Medicaid program will depend on participation by drug manufacturers and states. Patients would be subject to qualifications set by the negotiations between CMS and participating manufacturers, including certain prior authorization requirements.
cms.gov, Sep 29, 2026 - CMS: state Medicaid agencies can join BALANCE from May 2026 through January 1, 2027.Medicaid:
State Medicaid agencies can join the model beginning in May 2026 through January 1, 2027.
cms.gov, Sep 29, 2026